These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 7752202

  • 1. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M.
    J Med Chem; 1995 May 12; 38(10):1786-92. PubMed ID: 7752202
    [Abstract] [Full Text] [Related]

  • 2. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
    Amin KM, Ismail MM, Noaman E, Soliman DH, Ammar YA.
    Bioorg Med Chem; 2006 Oct 15; 14(20):6917-23. PubMed ID: 16843668
    [Abstract] [Full Text] [Related]

  • 3. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2.
    Monge A, Martínez-Crespo FJ, López de Ceráin A, Palop JA, Narro S, Senador V, Marín A, Sainz Y, González M, Hamilton E.
    J Med Chem; 1995 Oct 27; 38(22):4488-94. PubMed ID: 7473576
    [Abstract] [Full Text] [Related]

  • 4. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.
    Gali-Muhtasib HU, Haddadin MJ, Rahhal DN, Younes IH.
    Oncol Rep; 2001 Oct 27; 8(3):679-84. PubMed ID: 11295102
    [Abstract] [Full Text] [Related]

  • 5. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun 27; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
    Urquiola C, Vieites M, Torre MH, Cabrera M, Lavaggi ML, Cerecetto H, González M, Cerain AL, Monge A, Smircich P, Garat B, Gambino D.
    Bioorg Med Chem; 2009 Feb 15; 17(4):1623-9. PubMed ID: 19162490
    [Abstract] [Full Text] [Related]

  • 7. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
    Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2003 Jan 02; 46(1):169-82. PubMed ID: 12502371
    [Abstract] [Full Text] [Related]

  • 8. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 9. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents.
    Ortega MA, Morancho MJ, Martínez-Crespo FJ, Sainz Y, Montoya ME, López de Ceráin A, Monge A.
    Eur J Med Chem; 2000 Jan 15; 35(1):21-30. PubMed ID: 10733600
    [Abstract] [Full Text] [Related]

  • 10. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
    Riley RJ, Hemingway SA, Graham MA, Workman P.
    Biochem Pharmacol; 1993 Mar 09; 45(5):1065-77. PubMed ID: 8461036
    [Abstract] [Full Text] [Related]

  • 11. Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1α inhibitors with strong antiestrogenic potency.
    Buravchenko GI, Scherbakov AM, Dezhenkova LG, Bykov EE, Solovieva SE, Korlukov AA, Sorokin DV, Monzote Fidalgo L, Shchekotikhin AE.
    Bioorg Chem; 2020 Nov 09; 104():104324. PubMed ID: 33142432
    [Abstract] [Full Text] [Related]

  • 12. Structure-activity relationships for benzotriazine di-N-oxides.
    Zeman EM, Baker MA, Lemmon MJ, Pearson CI, Adams JA, Brown JM, Lee WW, Tracy M.
    Int J Radiat Oncol Biol Phys; 1989 Apr 09; 16(4):977-81. PubMed ID: 2703405
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI, Workman P.
    J Pharmacol Exp Ther; 1993 May 09; 265(2):938-47. PubMed ID: 8496834
    [Abstract] [Full Text] [Related]

  • 14. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.
    Naylor MA, Stephens MA, Nolan J, Sutton B, Tocher JH, Fielden EM, Adams GE, Stratford IJ.
    Anticancer Drug Des; 1993 Dec 09; 8(6):439-61. PubMed ID: 8286012
    [Abstract] [Full Text] [Related]

  • 15. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan 09; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 16. Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives.
    Vieites M, Noblía P, Torre MH, Cerecetto H, Laura Lavaggi M, Costa-Filho AJ, Azqueta A, de Cerain AL, Monge A, Parajón-Costa B, González M, Gambino D.
    J Inorg Biochem; 2006 Aug 09; 100(8):1358-67. PubMed ID: 16698084
    [Abstract] [Full Text] [Related]

  • 17. Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Johnson KM, Parsons ZD, Barnes CL, Gates KS.
    J Org Chem; 2014 Aug 15; 79(16):7520-31. PubMed ID: 25029663
    [Abstract] [Full Text] [Related]

  • 18. Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs.
    Wardman P, Priyadarsini KI, Dennis MF, Everett SA, Naylor MA, Patel KB, Stratford IJ, Stratford MR, Tracy M.
    Br J Cancer Suppl; 1996 Jul 15; 27():S70-4. PubMed ID: 8763850
    [Abstract] [Full Text] [Related]

  • 19. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
    Ismail MM, Amin KM, Noaman E, Soliman DH, Ammar YA.
    Eur J Med Chem; 2010 Jul 15; 45(7):2733-8. PubMed ID: 20236735
    [Abstract] [Full Text] [Related]

  • 20. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, Wilson WR.
    Biochem Pharmacol; 2012 Mar 01; 83(5):574-85. PubMed ID: 22182429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.